Zanubrutinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Zanubrutinib: From B-Cell Malignancies (CLL/SLL/MZL/WM) to Myeloid Leukemia
One-Sentence Summary
Zanubrutinib is a next-generation Bruton’s tyrosine kinase (BTK) inhibitor originally developed for B-cell lymphoid malignancies (CLL/SLL, Waldenström’s macroglobulinemia, marginal zone lymphoma). The TxGNN model predicts it may be effective for Myeloid Leukemia, but this direction is currently supported only by 2 indirectly related clinical trials (neither testing zanubrutinib as a myeloid-leukemia treatment) and 9 publications, none of which study zanubrutinib specifically in myeloid leukemia. The evidence base for this specific indication is therefore weak, and the mechanistic link is theoretical rather than demonstrated.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | B-cell malignancies (CLL/SLL/Waldenström’s macroglobulinemia/marginal zone lymphoma) — based on mechanistic rationale text; no Danish licence data available (not marketed in Denmark) |
| Predicted New Indication | Myeloid Leukemia |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L4 (mechanism/preclinical-level reasoning; no direct clinical or literature evidence for this specific indication) |
| Denmark Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for zanubrutinib is not available in this evidence pack (flagged as a High-severity data gap). Based on known pharmacology captured in the repurposing rationale, zanubrutinib is a covalent BTK inhibitor that blocks B-cell receptor (BCR) signalling, and all of its established indications are lymphoid malignancies (CLL/SLL, Waldenström’s macroglobulinemia, marginal zone lymphoma).
The proposed link to myeloid leukemia is mechanistic rather than clinical: TEC-family kinases, which include BTK, are expressed at some level in certain myeloid leukemia cells, and an earlier-generation BTK inhibitor (ibrutinib) has been explored experimentally in AML. This provides a plausible biological rationale for cross-class interest in BTK inhibition in myeloid disease, but it does not constitute direct evidence that zanubrutinib itself is active in myeloid leukemia.
Both identified clinical trials support this caveat: one tests CG-806 (luxeptinib), a different multi-kinase (FLT3/BTK/JAK) inhibitor, not zanubrutinib, in relapsed/refractory AML/MDS, and was terminated at Phase 1a/b; the other evaluates PRT2527 (a CDK9 inhibitor) alone or combined with zanubrutinib or venetoclax in relapsed/refractory hematologic malignancies generally, not myeloid leukemia specifically. The literature set likewise consists almost entirely of zanubrutinib’s established CLL/SLL/WM evidence base, not myeloid leukemia data. Taken together, the prediction should be read as a hypothesis-generating signal, not as clinically actionable evidence.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04477291 | Phase 1a/b | Terminated | 45 | Tested CG-806 (luxeptinib, a FLT3/BTK/JAK multi-kinase inhibitor) — not zanubrutinib — in relapsed/refractory AML or higher-risk MDS. Provides only indirect, same-target-class evidence; trial was terminated. |
| NCT05665530 | Phase 1 | Completed | 86 | Dose-escalation study of PRT2527 (a CDK9 inhibitor) as monotherapy and in combination with zanubrutinib or venetoclax in relapsed/refractory hematologic malignancies generally — not specific to myeloid leukemia. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39647999 | 2025 | RCT | J Clin Oncol | 5-year follow-up of SEQUOIA (NCT03336333): zanubrutinib vs bendamustine+rituximab in treatment-naïve CLL/SLL — supports established indication, not myeloid leukemia. |
| 40334067 | 2025 | Cohort | Blood Advances | Zanubrutinib well tolerated and effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib. |
| 40829104 | 2026 | Cohort | Blood Advances | Pooled analysis (SEQUOIA/ALPINE) of zanubrutinib efficacy/safety in CLL/SLL with del(17p)/TP53 mutation. |
| 36400069 | 2023 | Cohort | Lancet Haematol | Phase 2 single-arm study of zanubrutinib in B-cell malignancy patients intolerant of prior BTK inhibitors. |
| 34959482 | 2021 | Review | Pharmaceutics | Review of tyrosine kinase inhibitors in chronic leukemias (CML/CLL); general background, not zanubrutinib-specific myeloid data. |
| 36402930 | 2023 | Review | Leukemia | Review of BTK inhibitor use in Waldenström’s macroglobulinemia. |
| 37150651 | 2023 | Review | Clin Lymphoma Myeloma Leuk | Review of hepatitis B reactivation risk across BTK inhibitors (including zanubrutinib) — safety-related, not efficacy in myeloid leukemia. |
| 38288815 | 2024 | Review | Anticancer Agents Med Chem | Broad review of synthetic methodology for FDA-approved anticancer drugs (2018–2021); zanubrutinib mentioned only incidentally. |
| 36325357 | 2022 | Case Report | Front Immunol | Case report of coexisting Waldenström’s macroglobulinemia and B-cell ALL; not related to myeloid leukemia or zanubrutinib treatment. |
Denmark Market Information
Zanubrutinib currently holds no marketing authorisation on file for Denmark (market status: Not Marketed; 0 licences recorded). No Laegemiddelstyrelsen or EMA centralised authorisation data is available in this evidence pack.
Cytotoxicity
Zanubrutinib is an antineoplastic agent (BTK-inhibitor targeted therapy used across B-cell malignancy indications), so this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (oral small-molecule BTK inhibitor) — not a conventional cytotoxic chemotherapeutic |
| Myelosuppression Risk | Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions — no toxicity data available in this evidence pack |
| Emetogenicity Classification | Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions — no toxicity data available in this evidence pack |
| Monitoring Items | Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions — no toxicity data available in this evidence pack |
| Handling Protection | As an oral targeted small-molecule agent, cytotoxic-drug handling protections typically differ from conventional chemotherapy, but institutional policy and SmPC should be consulted directly |
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. No key warnings, contraindications, or drug interaction data are currently available in this evidence pack.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high, but there is no direct clinical or literature evidence of zanubrutinib activity in myeloid leukemia — both cited trials study different drugs, and all literature findings relate to zanubrutinib’s already-approved lymphoid indications. The evidence level (L4) reflects mechanistic plausibility only, and a Blocking-severity data gap (missing Danish label warnings/contraindications) prevents this candidate from progressing to a safety review (Stage S1).
To proceed, the following is needed:
- Danish/EU SmPC label data (warnings, contraindications) to clear the Blocking data gap and enable an initial safety assessment
- Confirmed detailed mechanism-of-action data (BTK/TEC-kinase expression evidence in myeloid leukemia subtypes)
- A clinical trial or preclinical study testing zanubrutinib itself (not a different kinase inhibitor) in a myeloid leukemia population
- Reassessment of whether the underlying TxGNN signal reflects a genuine biological relationship or a knowledge-graph embedding artifact, given the mixed disease specificity of other high-ranking predictions in this run (e.g., unrelated rare congenital syndromes and sarcomas at similar scores)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.